In the last three months, 14 analysts have published ratings on Arcellx (NASDAQ:ACLX), offering a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 11 | 3 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 9 | 3 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have recently evaluated Arcellx and provided 12-month price targets. The average target is $107.71, accompanied by a high estimate of $136.00 and a low estimate of $95.00. Marking an increase of 21.9%, the current average surpasses the previous average price target of $88.36.
Decoding Analyst Ratings: A Detailed Look
A clear picture of Arcellx's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Gil Blum | Needham | Maintains | Buy | $105.00 | $105.00 |
| Asthika Goonewardene | Truist Securities | Raises | Buy | $136.00 | $87.00 |
| Emily Bodnar | HC Wainwright & Co. | Raises | Buy | $115.00 | $95.00 |
| Biren Amin | Piper Sandler | Raises | Overweight | $115.00 | $91.00 |
| Gil Blum | Needham | Raises | Buy | $105.00 | $96.00 |
| Judah Frommer | Morgan Stanley | Raises | Overweight | $106.00 | $81.00 |
| Jason Gerberry | B of A Securities | Raises | Buy | $100.00 | $84.00 |
| Jack Allen | Baird | Raises | Outperform | $106.00 | $77.00 |
| Emily Bodnar | HC Wainwright & Co. | Raises | Buy | $95.00 | $80.00 |
| Gil Blum | Needham | Maintains | Buy | $96.00 | $96.00 |
| Gil Blum | Needham | Maintains | Buy | $96.00 | $96.00 |
| Gil Blum | Needham | Raises | Buy | $96.00 | $81.00 |
| Benjamin Burnett | Stifel | Raises | Buy | $122.00 | $83.00 |
| John Newman | Canaccord Genuity | Raises | Buy | $115.00 | $85.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Arcellx. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Arcellx compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Arcellx's stock. This comparison reveals trends in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Arcellx's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Arcellx analyst ratings.
Discovering Arcellx: A Closer Look
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
Breaking Down Arcellx's Financial Performance
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Arcellx's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 74.03%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Arcellx's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -99.37%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Arcellx's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -5.33%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Arcellx's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -3.45%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.14.
What Are Analyst Ratings?
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
